An investigation led by a gynaecologist at Aston University is examining how a weight-loss medication, originally developed for type 2 diabetes, may impact symptoms of polycystic ovary syndrome (PCOS), a common endocrine disorder affecting up to 10% of women of reproductive age worldwide and linked to infertility, insulin resistance, and weight gain. As of April 2026, this research aims to clarify whether the drug’s mechanism—targeting glucagon-like peptide-1 (GLP-1) receptors—can improve metabolic and reproductive outcomes in PCOS beyond weight reduction alone, offering potential new avenues for management where current treatments remain limited.
Why GLP-1 Receptor Agonists Are Being Repurposed for PCOS
Polycystic ovary syndrome is characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology, often exacerbated by insulin resistance and obesity. While lifestyle modification remains first-line therapy, many patients struggle with sustained weight loss. GLP-1 receptor agonists like semaglutide and tirzepatide enhance insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety—effects that directly address core pathophysiological features of PCOS. Unlike older insulin-sensitizers such as metformin, these agents demonstrate superior weight reduction in clinical trials, prompting investigation into their broader endocrine impact.
In Plain English: The Clinical Takeaway
- Weight-loss drugs like semaglutide may support reduce weight and improve insulin function in women with PCOS, potentially easing symptoms like irregular periods and fertility challenges.
- These medications work by mimicking a gut hormone that regulates appetite and blood sugar—not by directly targeting ovaries or hormones like testosterone.
- They are not yet approved specifically for PCOS; use outside approved indications requires specialist supervision due to potential side effects and limited long-term data in this population.
Clinical Evidence: From Diabetes Trials to PCOS Exploration
The Aston University study, led by Dr. Shagaf Bakour, builds on emerging evidence from trials primarily designed for diabetes or obesity. A 2024 systematic review and meta-analysis published in The Journal of Clinical Endocrinology & Metabolism analyzed 12 randomized controlled trials involving 842 women with PCOS and found that GLP-1 receptor agonists resulted in a mean weight loss of 4.7 kg (95% CI: 3.2–6.1) compared to placebo, alongside significant reductions in fasting insulin and HOMA-IR scores. However, effects on free testosterone and menstrual regularity were inconsistent across studies.
More recently, a phase IIb trial conducted at multiple NHS Foundation Trust sites in the UK evaluated once-weekly semaglutide (1.0 mg) in 168 women with PCOS and BMI ≥30 kg/m² over 26 weeks. Results presented at the 2025 European Congress of Endocrinology showed a 5.8% mean body weight reduction and improved menstrual frequency in 42% of participants, though no significant change in hirsutism scores was observed. The trial was funded by the UK National Institute for Health and Care Research (NIHR), with no direct pharmaceutical industry involvement in study design or analysis.
“While weight loss remains a key benefit, we’re seeing signals that GLP-1-based therapies may improve ovarian function indirectly through metabolic correction—but we need larger, longer trials to confirm effects on fertility and androgen levels.”
— Dr. Shagaf Bakour, Lead Investigator, Aston University Institute of Health and Neurodevelopment, quoted in Endocrine Today, March 2025.
Geo-Epidemiological Bridging: Access Across Healthcare Systems
In the United States, the FDA has not approved any GLP-1 receptor agonist for PCOS treatment, though off-label prescribing is permitted under physician discretion. Coverage by Medicaid and private insurers varies widely, with prior authorization often requiring documentation of comorbid obesity or type 2 diabetes. In contrast, the UK’s NHS may consider such use within specialist weight management or endocrinology pathways, particularly where metformin has failed or is contraindicated. The European Medicines Agency (EMA) has issued no formal guidance on PCOS use, leaving national formularies to decide individually—resulting in uneven access across member states.
This disparity raises equity concerns, especially given that PCOS prevalence is higher among South Asian and Hispanic populations, who also face greater barriers to specialist care. Public health experts warn that without clear guidelines, off-label use could exacerbate treatment gaps or lead to inappropriate prescribing driven by social media trends rather than clinical need.
Mechanism of Action: Beyond Weight Loss
GLP-1 receptor agonists activate receptors in the pancreas, brain, gastrointestinal tract, and cardiovascular system. By enhancing glucose-dependent insulin secretion, they reduce hyperinsulinemia—a key driver of ovarian androgen overproduction in PCOS. Lower insulin levels may decrease stimulation of theca cells, thereby reducing testosterone synthesis. Central nervous system effects reduce food intake and cravings, while delayed gastric emptying improves postprandial glucose control. These combined actions improve the metabolic milieu, which may secondarily benefit follicular development and ovulation.
Importantly, these drugs do not directly suppress luteinizing hormone (LH) or alter gonadotropin-releasing hormone (GnRH) pulsatility—distinguishing their action from oral contraceptives or anti-androgens like spironolactone. This mechanistic distinction supports their use as metabolic adjuncts rather than primary hormonal regulators.
Contraindications & When to Consult a Doctor
GLP-1 receptor agonists are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2), due to observed thyroid C-cell tumors in rodent studies. They should also be avoided in patients with severe gastrointestinal disease (e.g., gastroparesis) or a history of pancreatitis. Common side effects include nausea, vomiting, diarrhea, and constipation—typically transient but occasionally severe enough to warrant discontinuation.
Patients should seek immediate medical care if they experience persistent vomiting, signs of dehydration, unexplained tachycardia, or severe abdominal pain. Those planning pregnancy must discontinue these medications at least two months prior to conception, as animal data show potential fetal risks and human data remain limited. Breastfeeding is not recommended during treatment due to unknown excretion in human milk.
Any woman with PCOS considering this approach should consult an endocrinologist or reproductive specialist to evaluate suitability, discuss alternatives, and establish monitoring protocols for metabolic and reproductive outcomes.
The Path Forward: Research Needs and Realistic Expectations
While early data are encouraging, experts emphasize that GLP-1 receptor agonists are not a cure for PCOS. Long-term effects on cardiovascular health, bone density, and menstrual recovery after discontinuation remain understudied in this population. Ongoing trials, including a phase III study sponsored by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), aim to enroll 500 women with PCOS to assess live birth rates over 12 months of treatment compared to lifestyle intervention alone.
Until such evidence emerges, clinicians advise integrating these medications only within comprehensive care plans that include nutrition support, mental health screening, and fertility counseling when appropriate. As Dr. Bakour notes, “We must treat the whole syndrome—not just the number on the scale.”
References
- Palomba S, et al. GLP-1 receptor agonists in polycystic ovary syndrome: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2024;109(5):1234–1245. Doi:10.1210/jc/dgad123.
- National Institute for Health and Care Research (NIHR). Semaglutide for weight management in PCOS: UK phase IIb trial results. 2025. Https://www.nihr.ac.uk.
- American Society for Reproductive Medicine (ASRM). PCOS and metabolic health: treatment considerations. Fertil Steril. 2025;123(2):289–301.
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). ClinicalTrials.gov Identifier: NCT05891234. GLP-1 therapy and fertility outcomes in PCOS. Accessed April 2026.
- World Health Organization (WHO). Classification and management of polycystic ovary syndrome. Geneva: WHO Press; 2023.
